Product Program year 2025 Source: CMS Open Payments

Mytesi

Drug Infectious Disease

NDC 70564-802-60

Open in the dashboard

General payments

$1,050,445

8,657 payments

Research payments

$32,024

10 payments

Through program year 2025, $1,050,445 in general payments and $32,024 in research payments were reported against Mytesi (Infectious Disease).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

8 rows
Year Kind Amount Payments
2025 General $221,367 1,181
2024 General $188,245 1,382
2023 General $199,443 1,840
2022 General $223,620 1,142
2021 General $105,693 1,066
2020 General $17,558 607
2019 General $94,519 1,439
2019 Research $32,024 10

Breakdown

Who paid General payments · program years 2019–2025
  1. Napo Pharmaceuticals Inc $1,050,445 8,657 payments
Top recipients General payments · program year 2025
  1. Andrew Mulberg Pediatrics · Camden, NJ $31,773 14% · 13 payments
  2. Robin Beach Nurse Practitioner, Family · Houston, TX $22,601 10% · 16 payments
  3. Sandra Swain Hematology & Oncology · Bethesda, MD $15,726 7% · 12 payments
  4. Lissette Jimenez Pediatric Gastroenterology · Boston, MA $14,296 6% · 8 payments
  5. Brian Beesley Family Medicine · Columbus, OH $14,137 6% · 12 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Infectious Disease Internal Medicine $35,905 16% · 107 practitioners
  2. Pediatrics $31,773 14% · 1 practitioner
  3. Nurse Practitioner, Family Nurse Practitioner $28,844 13% · 131 practitioners
  4. Family Medicine $27,787 13% · 67 practitioners
  5. Gastroenterology Internal Medicine $23,998 11% · 15 practitioners

The top 5 of 39 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Texas $37,120 17% · 51 recipients
  2. New Jersey $32,489 15% · 24 recipients
  3. California $30,899 14% · 69 recipients
  4. Nevada $20,576 9% · 23 recipients
  5. Maryland $15,761 7% · 2 recipients

The top 5 of 32 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,674

Prescriptions dispensed, refills included

Drug cost

$4,749,288

Paid at the pharmacy, in all

Prescribers

89

With 11 or more claims of it

Medicare Part D drugs matched to Mytesi, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Mytesi Crofelemer Same name 89 1,674 $4,749,288

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 89 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
David Prelutsky Internal Medicine MO 73 $189,359 $1,276
Waref Azmeh Infectious Disease LA 54 $173,401 $57
Shawn Hassler Internal Medicine CA 49 $194,087 $181
Robert Wallace Family Practice FL 48 $123,082 $82
Stephen Adams Family Practice MO 47 $116,463 $95

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 89 with Patron
8,657 general · 10 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record